Scott Hensley
Stories By

Scott Hensley

Dr. William Burke goes over a PET brain scan in 2018 at Banner Alzheimer's Institute in Phoenix. The drug company Biogen has received federal approval for a medicine to treat early Alzheimer's disease. Matt York/AP hide caption

toggle caption
Matt York/AP

The FDA Has Approved A New Alzheimer's Drug — Here's Why That's Controversial

  • Download
  • <iframe src="https://www.npr.org/player/embed/1003964235/1004141650" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A health care worker holds a vial of the Johnson & Johnson COVID-19 vaccine at Klerksdorp Hospital in Klerksdorp, South Africa, on Feb. 18. PHILL MAGAKOE/AFP via Getty Images hide caption

toggle caption
PHILL MAGAKOE/AFP via Getty Images

A health care worker withdrew a dose of the Johnson & Johnson COVID-19 vaccine from a vial at the Klerksdorp Hospital in Klerksdorp, South Africa, on Feb. 18. Phill Magakoe/AFP via Getty Images hide caption

toggle caption
Phill Magakoe/AFP via Getty Images

A health care worker looks away as she's immunized with Johnson & Johnson's COVID-19 vaccine at Klerksdorp Hospital in Klerksdorp, South Africa, on Feb. 18. Phill Magakoe/AFP via Getty Images hide caption

toggle caption
Phill Magakoe/AFP via Getty Images

Pharmacy technician Sara Berech prepared a dose of the Johnson & Johnson COVID-19 vaccine in December for a clinical trial that includes Rocky Mountain Regional VA Medical Center in Aurora, Colo. Michael Ciaglo/Getty Images hide caption

toggle caption
Michael Ciaglo/Getty Images

Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19

  • Download
  • <iframe src="https://www.npr.org/player/embed/961887796/962022234" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Nurse Vash Deelchand inoculated Kate Bingham, chair of the U.K. government's vaccine task force, with a Novavax vaccine at the Royal Free Hospital in London in October. Kirsty O'Connor - PA Images/PA Images via Getty Images hide caption

toggle caption
Kirsty O'Connor - PA Images/PA Images via Getty Images

Novavax COVID-19 Vaccine Effective, But Less So Against Variant In South Africa

  • Download
  • <iframe src="https://www.npr.org/player/embed/961758633/961886655" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

A COVID-19 vaccine made by Moderna is next in line with the Food and Drug Administration for possible authorization for emergency use during the pandemic. Bill Sikes/AP hide caption

toggle caption
Bill Sikes/AP

A panel of advisers to the Food and Drug Administration met Thursday to evaluate Pfizer and BioNTech's COVID-19 vaccine and make recommendations on emergency use to the agency. A quick FDA decision is expected after the advisers' 17-4 vote. Jacquelyn Martin/AP hide caption

toggle caption
Jacquelyn Martin/AP

The authorization under consideration for the Pfizer/BioNTech vaccine would be for "individuals 16 years of age and older." John Nacion/SOPA Images/LightRocket/Getty Images hide caption

toggle caption
John Nacion/SOPA Images/LightRocket/Getty Images

Facebook and Twitter took action against social media posts released by President Trump from the White House on Tuesday morning. J. Scott Applewhite/AP hide caption

toggle caption
J. Scott Applewhite/AP

President Trump leaves the White House on Friday for Walter Reed National Military Medical Center, where he is expected to spend a few days "out of an abundance of caution." Drew Angerer/Getty Images hide caption

toggle caption
Drew Angerer/Getty Images